Reported about 7 hours ago
UBS has reiterated its Buy rating and $555 price target for Elevance Health, Inc. (NYSE:ELV) despite adjustments to the company's 2025 earnings expectations, which now predict first-half earnings to account for 60% of annual results, down from an earlier estimate of 62-63%. This change is attributed to factors such as clarity in ACA populations, billing issues in behavioral health, and slower Medicaid cost trends. Elevance plans to explore cost reduction strategies to enhance second-half performance.
Source: YAHOO